Medicines for high blood pressure in chronic kidney disease stage 3

Medicines for high blood pressure in chronic kidney disease: a Phase 3 studyIntroductionHigh blood pressure (arterial hypertension) in patients with chronic kidney disease (CKD) is common and represents a significant risk factor for the progression of kidney damage and cardiovascular events. The effective blood pressure control is considered a key strategy for slowing the progression of the CNE, and to the reduction of cardiovascular morbidity and mortality.ObjectiveThis Phase 3 study aims to investigate the efficacy and tolerability of the newly developed anti-hypertensive drugs in patients with CNE. In particular, the ability of the substances to reduce the glomerular filtration pressure in order to stabilize the renal function should be evaluated.MethodologyStudy type: multicenter, randomized, double-blind, placebo-controlled study.Participants: 500 adult patients aged 18-75 years with a diagnosis of chronic kidney disease (eGFR: 30 to 60\ \text{ml/min/1{,}73\ m^2}), and persistent high blood pressure (mean systolic blood pressure ≥140 mmHg).Intervention: The experimental group receives the newly developed drug (drug class: selective Endothelin‑Receptor Antagonist) in increasing doses (10 mg, 25 mg, 50 mg daily). The control group will receive Placebo.Comparator: standard therapy with ACE inhibitors or AT1‑Receptor blockers.Primary endpoint: change in the eGFR (estimated glomerular filtration rate) after 12 months.Secondary Endpoints:Reduction in systolic and diastolic blood pressure;Change in the proteinuria levels;Incidence of cardiovascular events (myocardial infarction, stroke);The frequency of adverse events and study discontinuations due to toxicity.Observation Period: 24 Months.Results (hypothetical)After 12 months the group that received the new drug showed a significantly lower decrease in the eGFR in comparison to the placebo group (p<0,05). The average reduction in systolic blood pressure was 18.2 mmHg in the intervention group compared to 8.5 mmHg in the placebo group. The proteinuria decreased in the intervention group and 35%, while in the placebo group, a reduction of 10% was found.The frequency of serious side effects (Hyperkalemia, acute renal failure) difference between the groups is not significant. The impact of the new drug was rated as good, with only 5% of the patients had to stop therapy.DiscussionThe results support the hypothesis that the selective Endothelin‑Receptor Antagonist in patients with CKD and hypertension receives the kidneys function better than standard therapy alone. The additional reduction in blood pressure and reduction of proteinuria could exert a protective effect on the kidneys.ConclusionThe study results suggest that the newly developed drug represents a promising Option for the treatment of hypertension in patients with chronic kidney disease. Further long-term studies are required to confirm the cardiovascular Outcomes and the long-term impact.Would you like me to make a certain section in more detail, or to add further Details to one aspect?

Ang mga modernong gamot sa pag-imprenta ay hinahati sa 10 iba't ibang grupo ayon sa kanilang mekanismo ng pagkilos. Pagkatapos suriin ng doktor ang mga reklamo ng pasyente at ang resulta ng mga pagsusuri, nagrereseta siya ng isa o higit pang gamot, na hindi dapat baguhin nang mag-isa. Ang mga gamot sa puso at daluyan ng dugo ay hindi kabilang sa mga puwedeng irekomenda sa kaibigan. Ang maling desisyon ay maaaring magdulot ng malungkot na kahihinatnan. Lahat ng gamot na pampababa ng presyon ng dugo ay kailangan ng reseta. Sa artikulong ito, tinitingnan natin ang kanilang modernong klasipikasyon base sa mga aktibong sangkap at sa paraan ng epekto nito sa katawan. Medicines for high blood pressure in chronic kidney disease stage 3. Minsan lang na biglaang pagtaas ng presyon o bahagyang mataas na resulta ay hindi palaging nangangailangan ng agarang pag-inom ng tableta. Lahat ng rekomendasyon ng mga espesyalista at ang mga magagamit na paraan ng pag-iwas ay mukhang simple lang, pero sa aktwal na buhay, ang maingat na pag-aalaga sa kalusugan ng dugo at sistema ng puso ay nakakaiwas sa biglaan at sobrang hindi kanais-nais na pagtaas ng presyon.

Syndromes, Cardiovascular Diseases

Propaedeutics Cardiovascular Diseases

Monoclonal antibodies against high blood pressure

Pulse against high blood pressure

72evakuator.ru/articles/20204-against-high-blood-pressure-clos.html

auto-expert-krd.ru/articles/20216-cardiovascular-disease-kazakhstan.html

Kung nagsimula na ang pag-inom ng gamot para sa mataas na presyon, hindi ibig sabihin na hindi na maaaring gawin ang karagdagang mga hakbang para palakasin ang katawan sa programa ng therapy. Ang benepisyo ng maingat na mga hakbang na pinagkasunduan ng doktor ay nakakatulong para mapigilan ang paglala ng sakit at maiwasang lumipat ito sa mas seryosong yugto. Kasabay nito, hindi inirerekomenda ang pangmatagalang pag-inom ng mga gamot mula sa kategoryang Diuretics, dahil ang mahahalagang sangkap tulad ng Potassium, Calcium, Magnesium ay mabilis na nailalabas sa katawan kasama ng sobrang tubig at asin. Alinsunod sa katangiang ito, sinasabayan ng mga Diuretics ang pag-inom ng mga gamot na may laman ng mga sangkap na ito. Maaaring ito ay mga vitamin at mineral na complexes, monokomponent, o mga suplemento sa pagkain na may napatunayang klinikal na bisa.